NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Down 2.3 %

NURO opened at $3.81 on Friday. NeuroMetrix has a 52-week low of $2.66 and a 52-week high of $4.73. The company has a market cap of $7.78 million, a P/E ratio of -0.83 and a beta of 2.18. The firm’s 50-day moving average price is $4.08 and its 200-day moving average price is $3.84.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. The company had revenue of $0.59 million for the quarter. During the same quarter in the prior year, the business posted ($1.66) EPS.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.